Therapeutic Treatments for Osteoporosis-Which Combination of Pills Is the Best Among the Bad?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Feb 15

PMID 35163315

Authors

Christian Horst Tonk

Sarah Hani Shoushrah

Patrick Babczyk

Basma El Khaldi-Hansen

Margit Schulze

Monika Herten

Edda Tobiasch

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a chronical, systemic skeletal disorder characterized by an increase in bone resorption, which leads to reduced bone density. The reduction in bone mineral density and therefore low bone mass results in an increased risk of fractures. Osteoporosis is caused by an imbalance in the normally strictly regulated bone homeostasis. This imbalance is caused by overactive bone-resorbing osteoclasts, while bone-synthesizing osteoblasts do not compensate for this. In this review, the mechanism is presented, underlined by in vitro and animal models to investigate this imbalance as well as the current status of clinical trials. Furthermore, new therapeutic strategies for osteoporosis are presented, such as anabolic treatments and catabolic treatments and treatments using biomaterials and biomolecules. Another focus is on new combination therapies with multiple drugs which are currently considered more beneficial for the treatment of osteoporosis than monotherapies. Taken together, this review starts with an overview and ends with the newest approaches for osteoporosis therapies and a future perspective not presented so far.

Citing Articles

Wnt/β-catenin signaling pathway: proteins' roles in osteoporosis and cancer diseases and the regulatory effects of natural compounds on osteoporosis.

Wang X, Qu Z, Zhao S, Luo L, Yan L Mol Med. 2024; 30(1):193.

PMID: 39468464 PMC: 11520425. DOI: 10.1186/s10020-024-00957-x.

Pro-differentiative, Pro-adhesive and Pro-migratory Activities of Isorhamnetin in MC3T3-E1 Osteoblasts via Activation of ERK-dependent BMP2-Smad Signaling.

Li J, Sun L, Wang F, Yin S, Li S, Zhang J Cell Biochem Biophys. 2024; 82(4):3607-3617.

PMID: 39136840 DOI: 10.1007/s12013-024-01450-2.

Exosomes: A New Hope for Angiogenesis-Mediated Bone Regeneration.

Lange M, Babczyk P, Tobiasch E Int J Mol Sci. 2024; 25(10).

PMID: 38791243 PMC: 11120942. DOI: 10.3390/ijms25105204.

Novel Osteoporosis Therapeutic Targets Derived from Medical Biotechnology.

Hajivalizadeh S, Akhondzadeh S Avicenna J Med Biotechnol. 2024; 16(1):1-2.

PMID: 38605738 PMC: 11005397. DOI: 10.18502/ajmb.v16i1.14164.

INSULIN RESISTANCE AND PATHOGENESIS OF POSTMENOPAUSAL OSTEOPOROSIS.

Greere D, Grigorescu F, Manda D, Lautier C, Poiana C Acta Endocrinol (Buchar). 2024; 19(3):349-363.

PMID: 38356971 PMC: 10863952. DOI: 10.4183/aeb.2023.349.

References

Garcia A, Tom C, Guemes M, Polanco G, Mayorga M, Wend K . ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis. J Bone Miner Res. 2012; 28(2):283-90. PMC: 3524410. DOI: 10.1002/jbmr.1747. View

Gremare A, Guduric V, Bareille R, Heroguez V, Latour S, LHeureux N . Characterization of printed PLA scaffolds for bone tissue engineering. J Biomed Mater Res A. 2017; 106(4):887-894. DOI: 10.1002/jbm.a.36289. View

Fouad-Elhady E, Aglan H, Hassan R, Ahmed H, Sabry G . Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model. Heliyon. 2020; 6(2):e03341. PMC: 7011045. DOI: 10.1016/j.heliyon.2020.e03341. View

Ehnert S, Baur J, Schmitt A, Neumaier M, Lucke M, Dooley S . TGF-β1 as possible link between loss of bone mineral density and chronic inflammation. PLoS One. 2010; 5(11):e14073. PMC: 2989906. DOI: 10.1371/journal.pone.0014073. View

Baron R, Ferrari S, Russell R . Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2010; 48(4):677-92. DOI: 10.1016/j.bone.2010.11.020. View

Clarke B . Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008; 3 Suppl 3:S131-9. PMC: 3152283. DOI: 10.2215/CJN.04151206. View

Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S . Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 1994; 9(11):1833-7. DOI: 10.1002/jbmr.5650091121. View

JOHNSTON Jr C, Bjarnason N, Cohen F, Shah A, Lindsay R, Mitlak B . Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med. 2000; 160(22):3444-50. DOI: 10.1001/archinte.160.22.3444. View

Alswat K . Gender Disparities in Osteoporosis. J Clin Med Res. 2017; 9(5):382-387. PMC: 5380170. DOI: 10.14740/jocmr2970w. View

10.

Khosla S, Oursler M, Monroe D . Estrogen and the skeleton. Trends Endocrinol Metab. 2012; 23(11):576-81. PMC: 3424385. DOI: 10.1016/j.tem.2012.03.008. View

11.

Ravn P, Clemmesen B, Riis B, Christiansen C . The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone. 1996; 19(5):527-33. DOI: 10.1016/s8756-3282(96)00229-3. View

12.

Cosman F, Dempster D . Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?. Curr Osteoporos Rep. 2021; 19(2):189-205. DOI: 10.1007/s11914-021-00663-1. View

13.

Delgado-Ruiz R, Swanson P, Romanos G . Systematic Review of the Long-Term Effects of Transgender Hormone Therapy on Bone Markers and Bone Mineral Density and Their Potential Effects in Implant Therapy. J Clin Med. 2019; 8(6). PMC: 6616494. DOI: 10.3390/jcm8060784. View

14.

Tsourdi E, Yu E, de Beur S, Drake M . Vaccination for Coronavirus Disease 2019 (COVID-19) and Relationship to Osteoporosis Care: Current Evidence and Suggested Approaches. J Bone Miner Res. 2021; 36(6):1042-1047. PMC: 8249992. DOI: 10.1002/jbmr.4304. View

15.

Khajuria D, Razdan R, Mahapatra D . The combination therapy with zoledronic Acid and propranolol improves the trabecular microarchitecture and mechanical property in an rat model of postmenopausal osteoporosis. J Osteoporos. 2014; 2014:586431. PMC: 3988934. DOI: 10.1155/2014/586431. View

16.

Zippel N, Limbach C, Ratajski N, Urban C, Luparello C, Pansky A . Purinergic receptors influence the differentiation of human mesenchymal stem cells. Stem Cells Dev. 2011; 21(6):884-900. DOI: 10.1089/scd.2010.0576. View

17.

Minisola S . Romosozumab: from basic to clinical aspects. Expert Opin Biol Ther. 2014; 14(9):1225-8. DOI: 10.1517/14712598.2014.920815. View

18.

Du Y, Guo J, Wang J, Mikos A, Zhang S . Hierarchically designed bone scaffolds: From internal cues to external stimuli. Biomaterials. 2019; 218:119334. PMC: 6663598. DOI: 10.1016/j.biomaterials.2019.119334. View

19.

Kogawa M, Wijenayaka A, Ormsby R, Thomas G, Anderson P, Bonewald L . Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J Bone Miner Res. 2013; 28(12):2436-48. DOI: 10.1002/jbmr.2003. View

20.

Yuan B, Wang L, Zhao R, Yang X, Yang X, Zhu X . A biomimetically hierarchical polyetherketoneketone scaffold for osteoporotic bone repair. Sci Adv. 2020; 6(50). PMC: 7732183. DOI: 10.1126/sciadv.abc4704. View